Acute orbital inflammation with loss of vision: a paradoxical adverse event associated with infliximab therapy for Crohn’s disease

References

• Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(1):159–169. doi:10.1586/1744666X.2014.866038.
   PubMed Web of Science ®Google Scholar
• Silva LCR, Ortigosa LCM, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanism of action and pitfalls. Immunotherapy. 2010;2(6):817–833. doi:10.2217/imt.10.67.
   PubMed Web of Science ®Google Scholar
• Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):1–12. doi:10.1136/rmdopen-2015-000239.
   Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto M-J, Cuadrado M-J, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheum. 2008;22:847–861. doi:10.1016/j.berh.2008.09.008.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Munoz S, Soria N, Galiana D, Bertolaccni L, et al. Autoimmune diseases induced by TNF-targeted therapies, analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242–251. doi:10.1097/MD.0b013e3181441a68.
   PubMed Web of Science ®Google Scholar
• Susanna FN, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophth Inflam Infect. 2020;10:1–9.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Perez-Alverez R, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents, a double edged sword? Autoimmun Rev. 2010;9:188–193. doi:10.1016/j.autrev.2009.10.003.
   PubMed Web of Science ®Google Scholar
• Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H, et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophth. 2019;4:1–6.
   Web of Science ®Google Scholar
• Barrie A, Plevy S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin N Am. 2006;35:883–893. doi:10.1016/j.gtc.2006.09.001.
   PubMed Web of Science ®Google Scholar
• Clemmensen K, Akrawi N, Staawowy M. Irreversible optic neuritis after infliximab in a patient with ulcerative colitis. Scan J Gastroent. 2015;50:1508–2151. doi:10.3109/00365521.2015.1063155.
   PubMed Web of Science ®Google Scholar
• Ouakaa-Kchaou A, Gargouri D, Trojet S, Hefaiedh R, Elloumi H, Kochlef A. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn’s disease. J Crohn’s Colilits. 2009;3:131–133. doi:10.1016/j.crohns.2009.02.007.
   PubMed Web of Science ®Google Scholar
• Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007;66:1255–1258. doi:10.1136/ard.2006.066787.
   PubMed Web of Science ®Google Scholar
• Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2010;248:283–287. doi:10.1007/s00417-009-1227-y.
   PubMed Web of Science ®Google Scholar
• Garcia-Medina JJ, Pastor-Grau A, del-Rio-Vellosillo M, Zanon-Moreno V, Pinazo-Duran MD. Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-yr follow-up. Scandinavian J Gastroenterol. 2016;51(6):765–766. doi:10.3109/00365521.2015.1126855.
   PubMed Web of Science ®Google Scholar
• Felikis T, Fatsanos K, Christodoulou D, Asproudis I, Tsianos EV. Reversible bilateral optic neuritis after infliximab discontinuation in a patient with Crohn’s disease. J Crohn’s and Colitis. 2009;3:212–214. doi:10.1016/j.crohns.2009.04.001.
   PubMed Web of Science ®Google Scholar
• Ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003;326:579. doi:10.1136/bmj.326.7389.579.
   PubMed Web of Science ®Google Scholar
• Landais A, Fanhan R. Optic neuritis associated to treatment with infliximab. Presse Med. 2017;46(3):337–342. doi:10.1016/j.lpm.2016.11.020.
   PubMed Web of Science ®Google Scholar
• Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthal. 2004;122:793–794. doi:10.1001/archopht.122.5.793.
   PubMed Web of Science ®Google Scholar
• Alexandre B, Vandermeeren Y, Dewit O, Moreels T, De Boer N, Dhar A, et al. Optic neuritis associated or not with TNF antagonists in patients with inflammatory bowel disease. J Crohn’s and Colitis. 2016;10(5):541–548. doi:10.1093/ecco-jcc/jjw003.
   PubMed Web of Science ®Google Scholar
• Taban M, Dupps W, Mandell B, Perez VL. Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocular Immunol. 2006;14:145–150. doi:10.1080/09273940600659393.
   PubMed Web of Science ®Google Scholar
• Katsanos A, Asproudis I, Katsanos KH, Dastiridou AI, Aspiotis M, Tsianos EV. Orbital and optic nerve complications of inflammatory bowel disease. J Crohn’s and Colitis. 2013;7:683–693. doi:10.1016/j.crohns.2012.09.020.
   PubMed Web of Science ®Google Scholar
• Badakere A, Patil-Chhablani P. Orbital Apex Syndrome: a review. Eye Brain. 2019;11:63–72. doi:10.2147/EB.S180190.
   PubMed Web of Science ®Google Scholar
• Foroozan YS. Orbital apex syndrome. Curr Opin Ophthalmol. 2004;15:490–498. doi:10.1097/01.icu.0000144387.12739.9c.
   PubMedGoogle Scholar
• Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017 Apr;389(10080):1741–1755. doi:10.1016/S0140-6736(16)31711-1.
   PubMed Web of Science ®Google Scholar
• Taylor SRJ, McCluskey P, Lightman S. The ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol. 2006;17:538–544. doi:10.1097/ICU.0b013e3280109461.
   PubMed Web of Science ®Google Scholar
• Hwang IP, Jordan DR, Acharya V. Lacrimal gland inflammation as the presenting sign of Crohn’s disease. Can J Ophthalmol. 2001 Jun;36(4):212–213. doi:10.1016/S0008-4182(01)80043-0.
   PubMed Web of Science ®Google Scholar
• Garity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004 Dec;138(6):925–930. doi:10.1016/j.ajo.2004.06.077.
   PubMed Web of Science ®Google Scholar
• Pimentel R, Lago P, Pedroto I. Recurrent orbital myositis as an extra-intestinal manifestation of Crohn’s disease. J Crohn’s Colitis. Oct 2012;6:958–959. doi:10.1016/j.crohns.2012.05.018.
   Google Scholar
• Monaghan TM, Albanese G, Kaye P, Thomas JD, Abercrombie LC, Moran GW. Orbital inflammatory complications of Crohn’s Diseases: a rare case series. Clin Med Insights: Gastroenterol. 2018;11:1–5.
   Google Scholar
• Ishihara R, Fouzdar J, Perry D, Reinhardt A, Suh D, Legge R. orbital pseudotumor as the presenting symptom of Crohn’s disease in male child. Am J Ophthalmol Case Reports. 2020;18:1–4. doi:10.1016/j.ajoc.2020.100669.
   Google Scholar
• Zenone T. Orbital myositis and Crohn’s disease. Int J Rheumat Dis. 2014;17:481–482. doi:10.1111/1756-185X.12238.
   PubMed Web of Science ®Google Scholar
• Vargason CW, Mawn LA. Orbital myositis as both a presenting and associated extraintestinal sign of Crohn’s disease. Ophthal Plast Reconstr Surg. 2017;33(3s Suppl 1):S158–S160. doi:10.1097/IOP.0000000000000475.
   PubMed Web of Science ®Google Scholar
• Farrell E, Sacks J. Infliximab-associated chiasmopathy. Ochsner J. 2008;8:140–145.
   PubMedGoogle Scholar
• Iwahashi C, Ono H, Haruta M, Minami T, Mashimo H, Shimojo H, et al. New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmol. Jul 2019;4(1):1–6. doi:10.1136/bmjophth-2018-000250.
   Web of Science ®Google Scholar
• Faillac C, de Almeida IRM, de Carvalho IF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013 Apr;33(4):1101–1103. doi:10.1007/s00296-011-2316-x.
   PubMed Web of Science ®Google Scholar
• Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120:985–987.
   PubMed Web of Science ®Google Scholar
• Bidagureu A, Muller-Thyssen A, Blanco A, Mendicute J, Ubeda M. Retrobulbar optic neuritis associated with infliximab. Arch Soc Esp Oftalmol. 2007;82:109–112. doi:10.4321/s0365-66912007000200009.
   PubMedGoogle Scholar
• Tran THC, Milea D, Cassoux N, Bodaghi B, Bourgeois P, LeHoang P. Optic neuritis associated with infliximab. J Fr Ophtamol. 2005;28:201–204. doi:10.1016/S0181-5512(05)81044-7.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Colombel J-F, Peyrin-Birouleth L. Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis. Gastroenterol Clin Biol. 2008;32:162–163. doi:10.1016/j.gcb.2008.01.003.
   PubMedGoogle Scholar
• Mumoli N, Niccoli G, Scazzeri F, Picchietti S, Greco A, Cei M. Infliximab-induced retrobulbar optic neuritis. QJM. 2007;100:531. doi:10.1093/qjmed/hcm060.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Hovenagel E, Goeb V, Fouache D, Martin A, Le Dantec P, et al. Development of inflammatory bowel disease during ant-TNF-α therapy for inflammatory rheumatic diseases: a nationwide series. Joint Bone Spine. 2012;79:457–463. doi:10.1016/j.jbspin.2011.10.001.
   PubMed Web of Science ®Google Scholar
• Singla MB, Hodge DK, Moawad FJ. Infliximab-induced anterior uveitis in a patient with ulcerative colitis. J Crohn’s Colitis. 2015;9(5):432–434. doi:10.1093/ecco-jcc/jjv030.
   Google Scholar
• Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. J Crohn’s Colitis. 2013;7:257–262. doi:10.1016/j.crohns.2012.06.024.
   Google Scholar
• Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020 Apr 27;10(1):11:1–9. doi:10.1186/s12348-020-00202-6.
   PubMed Web of Science ®Google Scholar